Lichen Planus
Clinical guidelines for managing T-cell mediated keratinocyte damage, distinguishing Wickham's striae, and reviewing mucosal immunomodulators.
Table of Contents
🧠 Standard of Care & Symptoms
Lichen Planus (LP) is a chronic inflammatory, autoimmune skin condition that can affect the skin, hair, nails, and mucous membranes.
- The Six Ps of Cutaneous LP:
- Planar: Flat-topped bumps.
- Purple: Violaceous (purplish) hue.
- Polygonal: Irregular, multi-sided shapes.
- Pruritic: Highly itchy.
- Papules & Plaques: Small raised lesions that can coalesce into larger patches.
- Wickham's Striae: Fine, white, lace-like lines traversing the surface of the purple papules, highly characteristic of LP.
- Oral & Mucosal Lichen Planus: Occurs in over 50% of patients, presenting as lacy white patches (reticular form) or painful, burning ulcers (erosive form) inside the cheeks and on the tongue.
- Pathophysiology: An autoimmune reaction where cytotoxic T-lymphocytes (CD8+) attack basal keratinocytes in the epidermis, causing liquefaction degeneration of the basal layer.
💊 Topical & Intralesional Injections
First-line therapies focus on controlling local T-cell activity to reduce itching and clear plaques.
Cortisone Therapies
- High-Potency Topical Corticosteroids: Clobetasol propionate (0.05% ointment) is the standard treatment for active skin plaques. For oral lichen planus, specialized dental pastes (e.g. Triamcinolone acetonide in Orabase) are used.
- Intralesional Injections: Injecting Triamcinolone acetonide directly into thick, hypertrophic plaques (often on the shins) provides rapid relief.
Non-Steroidal Topicals
- Topical Calcineurin Inhibitors (TCIs): Tacrolimus ointment is highly effective for erosive oral lichen planus, which is often resistant to topical steroids.
🛡️ Systemic & Phototherapy Regimens
For generalized cutaneous involvement or severe erosive mucosal lichen planus, systemic therapies are indicated.
- Systemic Corticosteroids: A brief course of oral Prednisone can be used to control acute, widespread eruptions.
- Oral Retinoids: Acitretin (20-30mg daily) helps normalize skin cell growth and is useful in hypertrophic and cutaneous variants.
- Narrowband UVB (NB-UVB) Phototherapy: Administered 2-3 times weekly, phototherapy suppresses skin immune cells and clears widespread cutaneous lesions safely.
🔬 Biopsy & Histopathological Hallmarks
When a skin biopsy is performed to confirm lichen planus, pathologists look for a distinct pattern of inflammation classified as a **lichenoid interface dermatitis**:
- Hyperkeratosis: Thickening of the outer skin layer (stratum corneum), notably *without* parakeratosis (cell nuclei are completely absent, unlike in psoriasis).
- Wedge-Shaped Hypergranulosis: Focal thickening of the granular layer of the epidermis, corresponding to the white Wickham's striae observed clinically.
- Sawtooth Rete Ridges: The downward projections of the epidermis (rete ridges) become pointed or "sawtooth" shaped due to basal cell damage.
- Band-Like Infiltrate: A dense band of T-lymphocytes hugging the dermo-epidermal junction, obscuring the border between the two layers.
- Civatte (Colloid) Bodies: Shrunken, apoptotic keratinocytes located in the lower epidermis and upper dermis, staining pink on H&E.
🔬 Active Clinical Trials
Clinical trials are currently evaluating oral JAK inhibitors, novel monoclonal antibodies targeting inflammatory cytokine pathways (IL-17, IL-23), and targeted oral immunosuppressants.
Evaluating the efficacy of a selective oral JAK1 inhibitor against placebo in moderate-to-severe cutaneous disease.
Key Inclusion: Age 18 to 65, biopsy-confirmed cutaneous lichen planus, total body surface area (BSA) affected ≥ 5%, and severe pruritus (itch score ≥ 6).Evaluating a novel subcutaneous monoclonal antibody targeting the IL-23 pathway in patients with severe, erosive oral lichen planus.
Key Inclusion: Moderate-to-severe erosive oral lichen planus, failed at least one high-potency topical steroid or calcineurin inhibitor, and willing to undergo serial oral photography.Testing a topical JAK inhibitor gel formulation for localized skin lesions to minimize systemic drug absorption.
Key Inclusion: Localized cutaneous lichen planus, maximum BSA affected ≤ 3%, and willing to wash out all topical steroids for at least 14 days prior.🗺️ Next Steps After Diagnosis
If you have recently been diagnosed with Lichen Planus, follow these steps to manage the disease:
- Confirm via Skin Biopsy: Ensure your dermatologist performs a punch biopsy to confirm the diagnosis and rule out other lichenoid eruptions.
- Schedule Regular Dental Exams: Erosive oral lichen planus carries a small (1-2%) risk of transforming into oral squamous cell carcinoma. Wounds should be monitored by a dental or oral medicine specialist every 6 months.
- Avoid the Koebner Phenomenon: Wounding, scratching, or rubbing the skin can trigger new LP plaques at the site of injury. Avoid scratchy washcloths and tight clothing.
- Review Current Medications: Some drugs (such as beta-blockers, NSAIDs, and antimalarials) can cause "lichenoid drug eruptions" that mimic LP. Review your medications with your doctor.
❓ Patient FAQ
Q: Is lichen planus related to fungal lichens on trees?
A: No. The disease gets its name simply because the dry, purple, lacy skin bumps look similar to the lichens that grow on trees and rocks. It is entirely an autoimmune inflammatory reaction, not a fungal infection.
Q: How long does cutaneous lichen planus typically last?
A: In most patients, cutaneous lichen planus is self-limiting, clearing spontaneously within 1 to 2 years. However, mucosal (oral) lichen planus is typically chronic, lasting for many years or decades with fluctuating activity.
Get the Free 2026 Clinical AI Directory
Email us at caleb@openphr.org to receive our exclusive directory of over 150 open-source models and clinical trial databases.